272 | La Lettre du Cancérologue • Vol. XXI - n° 5 - mai 2012
MISE AU POINT
Revue de la littérature sur lesfacteurs de risque de cancers du sein aprèsradiothérapie
21. Wahner-Roedler DL, Nelson DF, Croghan IT et al.
Risk of breast cancer and breast cancer characteristics
in women treated with supradiaphragmatic radiation for
Hodgkin lymphoma: Mayo Clinic experience. Mayo Clin
Proc 2003;78(6):708-15.
22. Bhatia S, Meadows AT, Robison LL. Second cancers after
pediatric Hodgkin’s disease. J Clin Oncol 1998;16(7):2570-2.
23. Constine LS, Tarbell N, Hudson MM et al. Subsequent
malignancies in children treated for Hodgkin’s disease:
associations with gender and radiation dose. Int J Radiat
Oncol Biol Phys 2008;72(1):24-33.
24. Inskip PD, Robison LL, Stovall M et al. Radiation dose and
breast cancer risk in the childhood cancer survivor study.
J Clin Oncol 2009;27(24):3901-7.
25. Chen J, Lee RJ, Tsodikov A, Smith L, Gaffney DK. Does
radiotherapy around the time of pregnancy for Hodgkin’s
disease modify the risk of breast cancer? Int J Radiat Oncol
Biol Phys 2004;58(5):1474-9.
26. Demoor-Goldschmidt C, Oberlin O, Vathaire FD
et al. Radio-induced breast cancers display aggressive
pathological characteristics: a retrospective study by the
French Pediatric Oncology Society (SFCE). ASTRO 2011:
abstr. 2948.
27. Swerdlow AJ, Barber JA, Hudson GV et al. Risk of second
malignancy after Hodgkin’s disease in a collaborative British
cohort: the relation to age at treatment. J Clin Oncol 2000;
18(3):498-509.
28. Bhatia S. Late effects among survivors of leukemia
during childhood and adolescence. Blood Cells Mol Dis
2003;31(1):84-92.
29. Sankila R, Garwicz S, Olsen JH et al. Risk of subsequent
malignant neoplasms among 1,641 Hodgkin’s disease
patients diagnosed in childhood and adolescence: a popula-
tion-based cohort study in the fi ve Nordic countries. Associa-
tion of the Nordic Cancer Registries and the Nordic Society
of Pediatric Hematology and Oncology. J Clin Oncol 1996;
14(5):1442-6.
30. Guibout C, Adjadj E, Rubino C et al. Malignant breast
tumors after radiotherapy for a fi rst cancer during childhood.
J Clin Oncol 2005;23(1):197-204.
31. Cutuli B, de La Rochefordière A, Dhermain F et al.
[Bilateral breast cancer after Hodgkin disease. Clinical and
pathological characteristics and therapeutic possibilities: an
analysis of 13 cases]. Cancer Radiother 1997;1(4):300-6.
32. Aisenberg AC, Finkelstein DM, Doppke KP et al. High risk
of breast carcinoma after irradiation of young women with
Hodgkin’s disease. Cancer 1997;79(6):1203-10.
33. Van Leeuwen FE, Klokman WJ, Veer MB et al. Long-term
risk of second malignancy in survivors of Hodgkin’s disease
treated during adolescence or young adulthood. J Clin Oncol
2000;18(3):487-97.
34. Mauch PM, Kalish LA, Marcus KC et al. Second malignan-
cies after treatment for laparotomy staged IA-IIIB Hodgkin’s
disease: long-term analysis of risk factors and outcome.
Blood 1996;87(9):3625-32.
35. Salloum E, Doria R, Schubert W et al. Second solid tumors
in patients with Hodgkin’s disease cured after radiation or
chemotherapy plus adjuvant low-dose radiation. J Clin Oncol
1996;14(9):2435-43.
36. Kenney LB, Yasui Y, Inskip PD et al. Breast cancer after
childhood cancer: a report from the childhood cancer
survivor study. Ann Intern Med 2004;141(8):590-7.
37. Hall EJ. Radiobiology for the radiologist. GAJ (ed.): 6e
édition; 2006.
38. Shore RE, Hildreth N, Woodard E et al. Breast cancer
among women given X-ray therapy for acute postpartum
mastitis. J Natl Cancer Inst 1986;77(3):689-96.
39. Garwicz S, Anderson H, Olsen JH et al. Second mali-
gnant neoplasms after cancer in childhood and adoles-
cence: a population-based case-control study in the 5 Nordic
countries. The Nordic Society for Pediatric Hematology and
Oncology. The Association of the Nordic Cancer Registries.
Int J Cancer 2000;88(4):672-8.
40. Henderson TO, Amsterdam A, Bhatia S et al. Systematic
review: surveillance for breast cancer in women treated with
chest radiation for childhood, adolescent, or young adult
cancer. Ann Intern Med 2010;152(7):444-55.
41. Hill DA, Gilbert E, Dores GM et al. Breast cancer risk
following radiotherapy for Hodgkin lymphoma: modifi ca-
tion by other risk factors. Blood 2005;106(10):3358-65.
42. Travis LB, Hill D, Dores GM et al. Cumulative absolute
breast cancer risk for young women treated for Hodgkin
lymphoma. J Natl Cancer Inst 2005;97(19):1428-37.
43. Tukenova M, Diallo I, Hawkins M et al. Long-term morta-
lity from second malignant neoplasms in 5-year survivors of
solid childhood tumors: temporal pattern of risk according
to type of treatment. Cancer Epidemiol Biomarkers Prev
2010;19(3):707-15.
44. Bhatti P, Veiga LH, Ronckers CM et al. Risk of second
primary thyroid cancer after radiotherapy for a childhood
cancer in a large cohort study: an update from the child-
hood cancer survivor study. Radiat Res 2010;174(6):741-52.
45. Shuryak I, Sachs RK, Brenner DJ. A new view of radia-
tion-induced cancer. Radiat Prot Dosimetry 2011;143(2-4):
358-64.
46. Antoniou A, Pharoah PD, Narod S et al. Average risks of
breast and ovarian cancer associated with BRCA1 or BRCA2
mutations detected in case series unselected for family
history: a combined analysis of 22 studies. Am J Hum Genet
2003;72(5):1117-30.
47. Boice JD Jr, Harvey EB, Blettner M, Stovall M, Flannery JT.
Cancer in the contralateral breast after radiotherapy for
breast cancer. N Engl J Med 1992;326(12):781-5.
48. Hooning MJ, Aleman BM, Hauptmann M et al. Roles
of radiotherapy and chemotherapy in the develop-
ment of contralateral breast cancer. J Clin Oncol 2008;
26(34):5561-8.
49. Svahn-Tapper G, Garwicz S, Anderson H et al. Radia-
tion dose and relapse are predictors for development of
second malignant solid tumors after cancer in childhood
and adolescence: a population-based case-control study
in the five Nordic countries. Acta Oncol 2006;45(4):
438-48.
50. De Bruin ML, Sparidans J, van’t Veer MB et al. Breast
cancer risk in female survivors of Hodgkin’s lymphoma:
lower risk after smaller radiation volumes. J Clin Oncol 2009;
27(26):4239-46.
51. Franklin J, Pluetschow A, Paus M et al. Second mali-
gnancy risk associated with treatment of Hodgkin’s
lymphoma: meta-analysis of the randomised trials. Ann
Oncol 2006;17(12):1749-60.
52. Lönn S, Gilbert ES, Ron E, Smith SA, Stovall M, Curtis RE.
Comparison of second cancer risks from brachytherapy and
external beam therapy after uterine corpus cancer. Cancer
Epidemiol Biomarkers Prev 2010;19(2):464-74.
53. Diallo I, Lamon A, Shamsaldin A et al. Estimation of the
radiation dose delivered to any point outside the target
volume per patient treated with external beam radiotherapy.
Radiother Oncol 1996;38(3):269-71.
54. Tinger A, Wasserman TH, Klein EE et al. The incidence
of breast cancer following mantle fi eld radiation therapy
as a function of dose and technique. Int J Radiat Oncol Biol
Phys 1997;37(4):865-70.
55. Chung CT, Bogart JA, Adams JF et al. Increased risk of
breast cancer in splenectomized patients undergoing radia-
tion therapy for Hodgkin’s disease. Int J Radiat Oncol Biol
Phys 1997;37(2):405-9.
56. O’Brien MM, Donaldson SS, Balise RR, Whittemore AS,
Link MP. Second malignant neoplasms in survivors of pedia-
tric Hodgkin’s lymphoma treated with low-dose radiation
and chemotherapy. J Clin Oncol 2010;28(7):1232-9.
57. Favier O, Heutte N, Stamatoullas-Bastard A et al.; Euro-
pean Organization for Research and Treatment of Cancer
(EORTC) Lymphoma Group and the Groupe d’Etudes des
Lymphomes de l’Adulte (GELA). Survival after Hodgkin
lymphoma: causes of death and excess mortality in patients
treated in 8 consecutive trials. Cancer 2009;115(8):1680-91.
58. Fermé C, Eghbali H, Meerwaldt JH et al.; EORTC-GELA
H8 Trial. Chemotherapy plus involved-fi eld radiation in
early-stage Hodgkin’s disease. N Engl J Med 2007;357(19):
1916-27.
59. Ferme C, Cosset JM, Fervers B et al.; French National
Federation of Cancer (FNCLCC). Hodgkins disease. Br J
Cancer 2001;84(Suppl 2):55-60.
60. Cosset JM, Fermé C, Henry-Amar M, Carde P. [The
role of radiotherapy for limited stage Hodgkin’s disease
in 1999: limitations and perspectives]. Cancer Radiother
1999;3(2):112-8.
61. Cosset JM, Henry-Amar M, Dietrich PY et al. [Secon-
dary solid tumors after Hodgkin’s disease radiotherapy;
experience at the Gustave-Roussy Institute]. Bull Cancer
1992;79(4):387-8.
62. Cosset JM, Henry-Amar M, Meerwaldt JH. Long-term
toxicity of early stages of Hodgkin’s disease therapy: the
EORTC experience. EORTC Lymphoma Cooperative Group.
Ann Oncol 1991;2(Suppl 2):77-82.
63. Schellong G, Brämswig JH, Schwarze EW, Wannen-
macher M. An approach to reduce treatment and invasive
staging in childhood Hodgkin’s disease: the sequence of
the German DAL multicenter studies. Bull Cancer 1988;
75(1):41-51.
64. Gocheva L. Radiation therapy in Hodgkin’s disease −
decades of steady progress. J BUON 2010;15(2):226-34.
65. Pommier P, Dussart S, Girinsky T et al. Impact of
18F-fluoro-2-deoxyglucose positron emission tomo-
graphy on treatment strategy and radiotherapy planning
for stage I-II Hodgkin disease: a prospective multicenter
study. Int J Radiat Oncol Biol Phys 2011;79(3):823-8.
66. Paumier A, Ghalibafi an M, Beaudre A et al. Involved-
node radiotherapy and modern radiation treatment tech-
niques in patients with Hodgkin lymphoma. Int J Radiat
Oncol Biol Phys 2011;80(1):199-205.
67. Koh ES, Tran TH, Heydarian M et al. A comparison of
mantle versus involved-fi eld radiotherapy for Hodgkin’s
lymphoma: reduction in normal tissue dose and second
cancer risk. Radiat Oncol 2007;2:13.
68. Colin C, Devic C, Noël A et al. DNA double-strand breaks
induced by mammographic screening procedures in human
mammary epithelial cells. Int J Radiat Biol 2011;87(11):1103-12.
69. Demoor-Goldschmidt C, Oberlin O, Vathaire F et al.
Second breast cancers, occuring after radiotherapy made
before the age of 30 years display aggressive pathological
characteristics. A retrospective study by the Société française
des cancers de l’enfant (SFCE). 2011.
Références bibliographiques (suite de la p. 272)